1. Tissue Repair Limited
Overview
A Regenerative Medicine Company
Week 1 Week 5 Week 10
Patient receiving TR-
987 treatment in a
Phase II Venus ulcer
trial. Patient’s
wound had not
closed for 6 months
with SoC
TR-987 initiated
wound repair and
closure1.
1. On average the drug recorded a 45% reduction in wound area over the trial for the completor cohort